Viewing Study NCT01025505


Ignite Creation Date: 2025-12-25 @ 3:25 AM
Ignite Modification Date: 2026-02-10 @ 12:20 PM
Study NCT ID: NCT01025505
Status: COMPLETED
Last Update Posted: 2022-10-12
First Post: 2009-12-01
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Treatment View
None Stem Cell Transplantation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Untreated Ph+ ALL unfit for intense therapy and allo SCT View